Cargando…
Immune response and reactogenicity after immunization with two-doses of an experimental COVID-19 vaccine (CVnCOV) followed by a third-fourth shot with a standard mRNA vaccine (BNT162b2): RescueVacs multicenter cohort study
BACKGROUND: There is no evidence to date on immunogenic response among individuals who participated in clinical trials of COVID-19 experimental vaccines redirected to standard national vaccination regimens. METHODS: This multicentre, prospective controlled cohort study included subjects who received...
Autores principales: | Ascaso-del-Rio, Ana, García-Pérez, Javier, Pérez-Olmeda, Mayte, Arana-Arri, Eunate, Vergara, Itziar, Pérez-Ingidua, Carla, Bermejo, Mercedes, Castillo de la Osa, María, Imaz-Ayo, Natale, Riaño Fernández, Ioana, Astasio González, Oliver, Díez-Fuertes, Francisco, Meijide, Susana, Arrizabalaga, Julio, Hernández Gutiérrez, Lourdes, de la Torre-Tarazona, Humberto Erick, Mariano Lázaro, Alberto, Vargas-Castrillón, Emilio, Alcamí, José, Portolés, Antonio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9249303/ https://www.ncbi.nlm.nih.gov/pubmed/35795398 http://dx.doi.org/10.1016/j.eclinm.2022.101542 |
Ejemplares similares
-
A third dose of the unmodified COVID-19 mRNA vaccine CVnCoV enhances quality and quantity of immune responses
por: Lenart, Klara, et al.
Publicado: (2022) -
Safety and immunogenicity of mRNA-LNP COVID-19 vaccine CVnCoV in Latin American adults: A phase 2 randomized study
por: Sáez-Llorens, Xavier, et al.
Publicado: (2022) -
Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial
por: Borobia, Alberto M, et al.
Publicado: (2021) -
mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents
por: Rauch, Susanne, et al.
Publicado: (2021) -
A Third Dose of the COVID-19 Vaccine, CVnCoV, Increased the Neutralizing Activity against the SARS-CoV-2 Wild-Type and Delta Variant
por: Wolz, Olaf-Oliver, et al.
Publicado: (2022)